NCT01242930Phase 2Completed

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2014-11Actual

Enrollment · participants13Actual

Source updated2026-06-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Multiple Myeloma

Treatments or interventions studied

Imetelstat (7.5 mg/kg)DrugAlso known as GRN163L
lenalidomide standard of careDrugAlso known as Revlimid
Imetelstat (9.4 mg/kg)DrugAlso known as GRN163L

Primary outcomes · main study measures

Read the study measures

measure: Rate of Improvement in Response; description: To determine the rate of improvement in response in patients with previously treated multiple myeloma following treatment with imetelstat alone or in combination wtih lenalidomide maintenance therapy. Response will be assessed using the International Uniform Response Criteria for Multiple Myeloma (IURCMM).; timeFrame: From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history